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Abstract
Prolactinomas are the most commonly encountered pituitary adenomas in the clinical setting. While most 
can be controlled by dopamine agonists, a subset of prolactinomas are dopamine-resistant and very 
aggressive. In such tumors, the treatment of choice is neurosurgery and radiotherapy, with or without 
temozolomide. 
Here, we report a patient with an highly aggressive, dopamine-resistant prolactinoma, who only achieved 
biochemical and tumor control during pasireotide long-acting release (PAS-LAR) therapy , a second-
generation somatostatin receptor ligand (SRL). Interestingly, cystic degeneration, tumor cell necrosis, or 
both was observed after PAS-LAR administration suggesting an antitumor effect.
This case shows that PAS-LAR therapy holds clinical potential in selective aggressive, dopamine-
resistant prolactinomas that express somatostatin (SST) receptor subtype 5 and appears to be a potential 
new treatment option before starting temozolomide. In addition, PAS-LAR therapy may induce cystic 
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Introduction
Prolactinoma is the most common hormone-secreting pituitary adenoma encountered in the clinical 
setting1. Hyperprolactinemia may result in hypogonadism, infertility and galactorrhea, while larger 
adenomas can produce mass effects by impinging on local structures2, 3. Whereas most prolactinomas 
are readily controlled by dopamine agonists (e.g., cabergoline), which activate tumoral dopamine subtype 
2 (D2) receptors, this is unsuccessful in up to 10% of patients4. Resistance to dopamine agonists is 
commonly defined as a failure to normalize prolactin and a less than 50% decrease in tumor diameter at 
a maximal labeled dose of 2.0 mg/week4. In contrast to prolactinomas in general, which most frequently 
present as microadenomas in young adult females, cabergoline resistant prolactinomas are 
characteristically macroadenomas and 46% of patients are males; genetic or familial disease is seen in 
13% of resistant cases5.
The recent guidelines on the management of aggressive pituitary tumors and carcinomas6 recommend 
that the highest tolerated dose of dopamine agonists, up to 11.0 mg/wk, can be used in patients with 
dopamine-resistant prolactinomas. We define aggressive pituitary tumors as multirecurrent and resistant 
to multimodal therapy including surgery and radiotherapy6. However, a study from Delgrange et al. 
showed that although this resistance to the prolactin-lowering effect of cabergoline is often partial and can 
be overcome in 75% of the cases by increasing the weekly dose up to 3.5  mg; little additional advantage 
was seen above a threshold of 3.5 mg/wk7. Transsphenoidal surgery (TSS) should also be considered in 
those tumors, either as total resection or debulking, while radiotherapy is reserved for uncommon patients 
(<5%) whose hyperprolactinemia and tumor cannot be controlled with surgery1, 8. Temozolomide 
chemotherapy has been used for very aggressive, dopamine-resistant macroprolactinomas, albeit with 
limited success4, 6.
First-generation somatostatin receptor ligands (SRLs) have not been found to be useful for 
treating prolactinomas since they bind primarily to somatostatin receptor subtype 2a (SST2a), while SST5 
is more important with respect to the regulation of prolactin secretion9. Pasireotide long-acting release 
(PAS-LAR) is a second-generation SRL, which binds to multiple SST receptors, but had particularly high 
affinity for SST5 receptor10. Despite the fact that most prolactinomas express SST5 receptors, the effects 
of first-generation SRLs that target SST5 receptor in in vitro studies are superimposable upon to those of 
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dopamine agonists and most dopamine-resistant prolactinoma cells are resistant to somatostatin 
analogues that bind to this receptor9, 11, 12. However, the clinical experience with PAS-LAR is that it is not 
restricted to activity via the SST5 receptor alone, as in acromegaly patients who are partially responsive to 
first-generation SRLs the responsiveness to PAS-LAR seems more driven by SST2a receptor13, while it is 
generally assumed that PAS-LAR is more effective when SST5 receptor is predominantly expressed14.
To date, there has only been one report of a dopamine-resistant prolactinoma treated by PAS-LAR15. 
Here we report a highly aggressive, dopamine-resistant prolactinoma that had an excellent biochemical 
and tumor response, including tumor shrinkage and rapid antitumor effects. This case shows that PAS-
LAR therapy holds clinical potential in selective aggressive, dopamine-resistant prolactinomas that 




The proband was a 61-year-old woman referred to our institution for evaluation of a dopamine-resistant 
prolactinoma. She presented initially to a local hospital at the age of 25 with secondary amenorrhea and 
was found to have hyperprolactinemia (levels unavailable). She had no clinical features of hypopituitarism 
and was not taking any medication. Magnetic resonance imaging (MRI) of the pituitary gland revealed a 
macroadenoma. She initially received bromocriptine therapy (2.5 mg three times daily), and the prolactin 
levels normalized, although her menses were not restored. Six years later, she developed bitemporal 
hemianopia and was again found to be hyperprolactinemic on bromocriptine therapy. She underwent TSS 
with the goal of gross-total resection. Post-operatively she had hyperprolactinemia and a tumor remnant. 
She was placed on bromocriptine again (2.5 mg three times daily) and was controlled compared with her 
pre-operative situation. Three years later the proband presented for a second time with bitemporal 
hemianopia and hyperprolactinemia during bromocriptine therapy (2.5 mg three times daily), and she 
underwent second TSS with postsurgical conventional radiotherapy (total dose: 50.4 gray (Gy)). During 
the post-operative period, she developed thyroid and adrenal insufficiency. Postoperatively she had a 
tumor remnant and hyperprolactinemia that again necessitated bromocriptine therapy (2.5 mg three times 
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daily). Again, six years later the bitemporal hemianopia and hyperprolactinemia returned during 
bromocriptine therapy (2.5 mg three times daily), but now she underwent gamma knife radiosurgery (total 
dose: 15 Gy). Cabergoline monotherapy (0.5 mg/wk) was afterwards initiated and increased up to 3.0 
mg/wk during the next five years. During the next two years her prolactin levels were normalized, but 
eventually therapy failed and both hyperprolactinemia and clinically relevant tumor growth occurred again 
(prolactin level 227.36 ng per milliliter [4837 mU per liter], tumor size 2549 mm3). It is important to note 
that for all surgical and radiotherapy interventions the reason of conduct was both hyperprolactinemia and 
bitemporal hemianopia, demonstrating the persistent recurrence of this tumor.
At this point the proband was referred to our institution. Histology of the excised specimen from 
first and second pituitary surgery were evaluated. Histology of the first surgical excised specimen 
revealed an adenoma, consisting of cells with moderate amounts of eosinophilic fine granular cytoplasm 
and nuclei with fine granular chromatin. Almost all tumor cells were positively stained for prolactin (Fig. 1), 
while there was no staining for GFAP, ACTH, GH, FSH, LH and TSH. Ki-67 (Mib-1) staining showed 5-
10% expression in the tumoral cells and no overexpression of p53 (Fig. 1)16. The pituitary tissue was 
immunostained for SST2a and SST5 receptor by using the rabbit monoclonal anti-SST2a receptor antibody 
clone UMB-1 (SS-8000; BioTrend, Köln, Germany) at a dilution of 1:50 and the rabbit monoclonal anti-
SST5 receptor antibody clone UMB-4 at a dilution of 1:400 (ab109495; Abcam, Cambridge, United 
Kingdom). SST receptor subtyping was evaluated using an immunoreactivity score (IRS)17, 18, showing 
membranous expression of IRS 9 for SST2a receptor and IRS 12 for SST5 receptor (Fig. 1). We classified 
this tumor as grade 2b, indicating an invasive and a proliferative tumor, according to Trouillas and 
colleagues19 as the tumor was a macroadenoma, stained for prolactin, invaded the cavernous sinus, and 
showed proliferative markers (Ki-67 5-10% and 8 mitotic figures with 10 high power field). 
Immunohistochemistry of the residual tumor revealed, in contrast to first surgery, membranous expression 
score of IRS 6 for SST2a receptor whereas SST5 receptor remained IRS 12 (data not shown). The 
difference in SST2a expression after the second surgery could be due to molecular events in the tumor, 
which contribute to the change in tumor behavior. However, the molecular events responsible for reduced 
SSTs receptor expression are still largely unknown20. The proliferative markers from the second surgery 
did not differ from the first. There was no family history of pituitary or endocrine neoplasia and 
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investigations for germline mutations in the aryl hydrocarbon receptor-interacting protein (AIP), multiple 
endocrine neoplasia type 1 (MEN1), cyclin-dependent kinase inhibitor 1B (CDKN1B) genes and multiplex 
ligation-dependent probe amplification (MLPA) studied for deletions in these genes detected no 
abnormalities. Prolactin levels in response to different medical therapies are shown in Figure 2. At follow-
up, she was treated with a higher dosage of cabergoline up to 5.0 mg/wk for three months, while prolactin 
levels along with tumor size tended to increase still further. To determine whether maximum dose of co-
treatment with first-generation SRL lanreotide autogel 120 mg/month would have an additional effect, she 
took combination therapy with lanreotide and cabergoline for 10 months. Hyperprolactinemia and 
clinically relevant tumor growth, however, remained unchanged and cabergoline dose was increased 
further up to 7.0 mg/wk7, while lanreotide was discontinued. After 16 months follow-up, this high-dose of 
cabergoline failed to normalize prolactin levels nor had it reduced tumor volume (there were no visual 
field defects). 
We decided to start PAS-LAR in combination with cabergoline to determine whether it could 
achieve biochemical and tumor control, particularly given the presence of multiple SST receptors in tumor 
specimens. Written informed consent was obtained from the proband for genetic studies and for 
publication of this case report, in accordance with the Declaration of Helsinki. 
Treatment
PAS-LAR was initiated at a dose of 60.0 mg/month, while cabergoline was continued at 7.0 mg/day. 
Regular electrocardiograms and biochemical monitoring were performed, including prolactin and insulin-
like growth factor I (IGF-I) levels, fasting plasma glucose (FPG) and glycosylated hemoglobin (HbA1c) 
levels, and analysis of renal and liver function. The proband has no pre-existing impaired glucose 
metabolism before initiating PAS-LAR according to the American Diabetes Association (ADA) criteria21. 
MRI examinations were collected for central reading and an experienced neuroradiologist (K.P) evaluated 
MRIs in the Picture Archive Communication System (PACS, Sectra®, Linköping, Sweden). 
 
Results
Biochemical response to PAS-LAR
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The response to combination therapy with PAS-LAR and cabergoline in the proband is shown in Figure 2. 
Co-treatment with PAS-LAR and cabergoline achieved prolactin normalization within two months, which 
has been sustained to date for a duration of 31 months (Fig. 2). The dose of cabergoline was gradually 
tapered down from 3.5 mg/wk after five months and to 1.5 mg/wk after 27 months of PAS-LAR, because 
echocardiographic screening revealed the new onset of clinically significant valvular heart disease. PAS-
LAR was well tolerated and has not been complicated by common side effects such as hyperglycemia, 
diarrhea, abdominal pain, nausea or other related side effects22. HbA1c levels increased from 5.4% 
(normal value, <7%) before start of PAS-LAR to 6.2% after 6 months of treatment and remained relatively 
stable at 6.3% after 18 months of treatment without antidiabetic therapy. Moreover, FPG levels remained 
<5.7 mmol per liter during PAS-LAR, indicating normal glucose tolerance according to ADA criteria21. 
Other laboratory assessments have shown reduced levels of IGF-I (25.9 at baseline - normal value, <24.3 
nmol per liter; to 6.1 nmol per liter after 6 months of treatment; normal value, <22.0 nmol per liter) and 
normal renal and liver function during the follow-up. At this point, she is still continuing the combination 
therapy with PAS-LAR (60.0 mg/month) and cabergoline (1.5 mg/wk). 
Tumor response to PAS-LAR
The volumetric tumor response on gadolinium-enhanced T1-weighted MRI during PAS-LAR initiation are 
shown in Figure 3. PAS-LAR in combination with low-dose cabergoline markedly reduced the tumor size: 
the tumor volume reduced from 4660 mm3 before initiation of PAS-LAR to 3900 mm3 during 5 months, 
halved to 1800 mm3 during 13 months, and reduced further to 1300 mm3 during 23 months of treatment 
(Fig. 3). 
Interestingly, using the visual assessment and the T1-signal intensity of the adenoma, we observed an 
increase in T1-signal heterogeneity of the adenoma. This was particularly clear on the MRI performed five 
months after initiating PAS-LAR therapy (Fig. 3). Moreover, visual assessment and the quantification of 
the T2-weighted signal by Region Of Interest (ROI) measurement of the adenoma showed a higher T2-
signal intensity ratio during treatment: ROI adenoma/ gray matter ratio was 0.89 at baseline, increased to 
1.47 during 13 months of treatment and remained increased during 23 months of PAS-LAR treatment in 
combination with low-dose cabergoline (Fig. 3). In general, heterogeneity on T1- and a T2-hyperintense 
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signal indicates cystic degeneration, tumor cell necrosis, or both, which suggest an antitumor effect of 
PAS-LAR. Signs for cystic degeneration, tumor cell necrosis, or both, were particularly clear on the MRI 
performed five months after initiating PAS-LAR therapy (Fig. 3). 
Discussion
The management of dopamine-resistant and/or aggressive prolactinomas poses a therapeutic challenge. 
The successful use of PAS-LAR treatment in combination with low-dose cabergoline in a highly 
aggressive, dopamine-resistant prolactinoma that expressed SST5 receptor, reported here, appears to be 
a potential new treatment option before starting temozolomide therapy. 
The decision to start with PAS-LAR was made by a multidisciplinary team after concluding that 
radiotherapy would not be a treatment option since maximal dose of radiotherapy had been reached. As 
mentioned above, radiotherapy is reserved as a treatment option before starting with temozolomide 
chemotherapy (radiotherapy, however, was not performed in the recent case reported by Lasolle and 
colleagues15). Moreover, surgery had previously failed to be curative on multiple occasions and 
cabergoline resistance was worsening and additional medical treatment was likely to be needed. An 
important argument supporting a trial use of PAS-LAR in combination with cabergoline was the absence 
of visual field defects, which provided a window of opportunity. 
At the start of PAS-LAR, cabergoline therapy was continued to ensure the evaluation of efficacy 
only applied to the addition of PAS-LAR therapy. Cabergoline combined with a SST5 receptor analog may 
have a possible partial synergistic effect in suppressing prolactin secretion9. However, when the dose of 
cabergoline was gradually tapered down in our proband, long-term biochemical and tumor response has 
been sustained to date, implying that PAS-LAR is a key player. Since cabergoline was not associated 
with an antitumor effect and induced clinically significant valvular heart disease in our proband, the 
multidisciplinary team decided last month to stop cabergoline therapy.
Although Raverot and colleagues6 recommend that the highest tolerated dose of cabergoline should be 
used in patients displaying dopamine-resistant prolactinomas, this approach is justified as long as there is 
continued response to the increased dose and no adverse effects. Therefore, we decided not to increase 
the dosage further beyond 7.0 mg/wk, because both her prolactin levels and tumor volume were 
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unresponsive to the cabergoline dose increases. This was expected, since dopamine-resistant 
prolactinomas often express a lower number of D2 receptors, explaining the only partial effect of 
dopamine agonists9, 23. Furthermore, high doses of cabergoline carry the risk of cardiac valvular 
regurgitation1, 24, 25, which was seen in this patient. Cardiac fibrosis of heart leaflets appears to be an 
irreversible process. To minimize the exposure to cabergoline, one could argue that PAS-LAR therapy 
holds potential in patients where high-dose (>3.0 mg/wk) cabergoline treatment is indicated to suppress 
the prolactinoma.
Current evidence indicates that PAS-LAR therapy seems unlikely to be effective since most of 
dopamine-resistant prolactinomas appear to express no or low levels of SST5 receptor and are resistant 
to second-generation SRLs that bind to this receptor9. The good response to PAS-LAR therapy in our 
proband may be explained by the remarkable high expression of SST5 receptor levels (IRS 12) in the 
prolactinoma. In the case from Lasolle et al., SST receptor subtyping was evaluated using the percentage 
of positive cells and not the staining intensity15. The same IRS scoring system can be applied for SST5 
receptor expression in their case, and the product of the percentage of positive stained cells (2: 10-50%) 
and the staining intensity (2: moderate staining) would amount to a maximum IRS score of 4, which 
corresponds with moderate expression. Therefore, our results support the possibility of good clinical 
responses to PAS-LAR therapy in prolactinomas for which SST5 receptor expression is significant. 
Based on our clinical experiences treating dopamine-resistant prolactinoma patients with 
cabergoline and first-generation SRL combination therapy, we observed that in several cases co-
treatment with SRLs may suppress prolactin levels. However, after ten months of first-generation SRL 
therapy with lanreotide there was no effect in suppressing prolactin secretion in our case. In addition, 
lower potency of the first-generation SRL in reducing prolactin secretion is related to lower SST2a receptor 
levels9; intermediate levels of SST2a receptor (IRS 6) were present on the prolactinoma in our proband 
after the second operation.
In contrast to the previous case15, we observed tumor size reduction after PAS-LAR 
administration. Although activation of specific SST subtypes may explain this discrepancy, as the 
mechanisms responsible for inhibition of cell proliferation in pituitary tumors are mediated by both SST2 
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and SST5 receptor activation26, and the observed tumor shrinkage can be assigned to the higher 
expression of these SSTs receptors in our case.
Interestingly, as shown in our and the previous case15, PAS-LAR therapy might induce cystic 
degeneration, tumor cell necrosis, or both. Coopmans and co-workers, however, also recently reported 
increased T2-weigthed MRI signal of the adenoma in 14 (30.0%) of 47 acromegaly patients suggestive 
for cystic degeneration, tumor cell necrosis, or both, during PAS-LAR treatment27. No new-onset anterior 
pituitary deficiencies were observed in our proband, the previous case15 or in the acromegaly cohort27. 
Therefore, we recommend close monitoring of pituitary tumor status, alongside regular assessment of 
prolactin concentrations, and, in case of substantial necrosis to reconsider the treatment regimen. 
Among the SST receptor subtypes only SST2 and SST3 might be responsible for the 
somatostatin-induced apoptosis. Whether a subgroup of patients will benefit from targeting these 
receptors with a multireceptor ligand with an improved affinity for SST3 receptor remains to be elucidated. 
However, immunohistochemistry with the rabbit monoclonal anti-human SST3 receptor antibody UMB-5 
were not performed due to limited specificity for the SST3 receptor28. 
A noted side effect of PAS-LAR is the frequent development of hyperglycemia. The proband had 
good glycemic control while receiving PAS-LAR therapy: although HbA1c levels did rise after PAS-LAR 
administration, still she has not developed diabetes according to the ADA criteria21. This might be due to 
the fact that she has no pre-existing impaired glucose metabolism before initiating PAS-LAR, while 
elevated HbA1c and FPG levels at baseline are strong predictors for developing hyperglycemia among 
acromegaly patients29. 
This individual patient report further underlines the role of SST5 receptor in mediating its 
suppressive effect on prolactinomas. However, the potential clinical importance of these findings should 
be considered as relating to a very specific group of patients, namely those with aggressive 
prolactinomas expressing moderate to high levels of SST5 receptor. In this setting PAS-LAR responses 
can include normalization of prolactin levels, tumor shrinkage, and perhaps cystic degeneration or tumor 
cell necrosis.
9, 11, 12 In conclusion, this case shows that in selective patients with aggressive and dopamine-resistant 
prolactinomas, PAS-LAR therapy holds clinical potential in prolactinomas that express high affinity for 
Page 10 of 17Accepted Manuscript published as EJE-19-0279.R1. Accepted for publication: 05-Jun-2019
Copyright © 2019 European Society of Endocrinology Downloaded from Bioscientifica.com at 06/06/2019 08:59:53AM
via ESE MEMBER ACCESS
SST5 receptor and appears to be a potential new treatment option before starting temozolomide therapy. 
In addition, PAS-LAR therapy may induce cystic degeneration, tumor cell necrosis, or both, of pituitary 
tumors in prolactinomas.
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Figure legends
Figure 1. Following first pituitary surgery. Immunohistochemistry for prolactin (A) showing strong 
expression of prolactin in most lesional cells, Ki-67 (Mib-1) (B) showing staining in 5-10% of the lesional 
cells without overexpression of p53 (C). Immunohistochemistry for SST2a receptor (D) showing 
membranous staining IRS 9, SST5 receptor (E) with IRS 12 after first surgery. IRS: immunoreactivity 
score
Figure 2. Prolactin levels in response to different medical therapies during the academic clinical 
follow-up of the proband. Time (months) = 0 represents the time point of the referral to our institution. 
Data are shown until 60 months. CAB: cabergoline; LAN: lanreotide autogel; ng/ml: nanogram per 
milliliter; PAS-LAR: pasireotide long-acting release; ULN: upper limit of normal; wk: week. 
Figure 3. MRI scans showing T1- and T2-signal intensity, and tumor shrinkage during treatment 
with PAS-LAR in combination with low-dose cabergoline. 
Gadolinium-enhanced T1 and T2-weighted MRI scans obtained before initiation of PAS-LAR therapy, 
showing a large prolactinoma (left scan, tumor marked in red) during 5, 13 and 23 months of treatment, 
with marked reduction of the mass (second, third and fourth scan, tumor marked in red). Both visual 
assessment and the quantification of the T2-weighted signal by ROI measurement of the adenoma shows 
a higher T2-signal intensity during PAS-LAR treatment. PAS-LAR: pasireotide long-acting release; ROI: 
Region Of Interest.
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and the quantification of the T2-weighted signal by ROI measurement of the adenoma shows a higher T2-
signal intensity during PAS-LAR treatment. PAS-LAR: pasireotide long-acting release; ROI: Region Of 
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